Exagen Inc.

NasdaqGM:XGN Stock Report

Market Cap: US$83.1m

Exagen Future Growth

Future criteria checks 1/6

Exagen is forecast to grow earnings and revenue by 24.7% and 13.7% per annum respectively while EPS is expected to grow by 29.6% per annum.

Key information

24.7%

Earnings growth rate

29.6%

EPS growth rate

Biotechs earnings growth27.7%
Revenue growth rate13.7%
Future return on equityn/a
Analyst coverage

Good

Last updated13 Nov 2024

Recent future growth updates

Analyst Estimates: Here's What Brokers Think Of Exagen Inc. (NASDAQ:XGN) After Its Second-Quarter Report

Aug 07
Analyst Estimates: Here's What Brokers Think Of Exagen Inc. (NASDAQ:XGN) After Its Second-Quarter Report

Analysts Have Made A Financial Statement On Exagen Inc.'s (NASDAQ:XGN) Annual Report

Mar 22
Analysts Have Made A Financial Statement On Exagen Inc.'s (NASDAQ:XGN) Annual Report

Recent updates

Exagen Inc.'s (NASDAQ:XGN) Share Price Boosted 26% But Its Business Prospects Need A Lift Too

Dec 22
Exagen Inc.'s (NASDAQ:XGN) Share Price Boosted 26% But Its Business Prospects Need A Lift Too

Improved Revenues Required Before Exagen Inc. (NASDAQ:XGN) Stock's 40% Jump Looks Justified

Sep 06
Improved Revenues Required Before Exagen Inc. (NASDAQ:XGN) Stock's 40% Jump Looks Justified

Analyst Estimates: Here's What Brokers Think Of Exagen Inc. (NASDAQ:XGN) After Its Second-Quarter Report

Aug 07
Analyst Estimates: Here's What Brokers Think Of Exagen Inc. (NASDAQ:XGN) After Its Second-Quarter Report

Insufficient Growth At Exagen Inc. (NASDAQ:XGN) Hampers Share Price

Jul 13
Insufficient Growth At Exagen Inc. (NASDAQ:XGN) Hampers Share Price

Is Exagen (NASDAQ:XGN) Using Debt In A Risky Way?

May 21
Is Exagen (NASDAQ:XGN) Using Debt In A Risky Way?

Why Investors Shouldn't Be Surprised By Exagen Inc.'s (NASDAQ:XGN) 31% Share Price Plunge

Mar 26
Why Investors Shouldn't Be Surprised By Exagen Inc.'s (NASDAQ:XGN) 31% Share Price Plunge

Analysts Have Made A Financial Statement On Exagen Inc.'s (NASDAQ:XGN) Annual Report

Mar 22
Analysts Have Made A Financial Statement On Exagen Inc.'s (NASDAQ:XGN) Annual Report

Exagen Inc.'s (NASDAQ:XGN) Business And Shares Still Trailing The Industry

Jul 21
Exagen Inc.'s (NASDAQ:XGN) Business And Shares Still Trailing The Industry

Exagen appoints John Aballi as CEO

Oct 17

Analysts Just Slashed Their Exagen Inc. (NASDAQ:XGN) EPS Numbers

Aug 10
Analysts Just Slashed Their Exagen Inc. (NASDAQ:XGN) EPS Numbers

Exagen (NASDAQ:XGN) Has Debt But No Earnings; Should You Worry?

Jul 26
Exagen (NASDAQ:XGN) Has Debt But No Earnings; Should You Worry?

Is Exagen (NASDAQ:XGN) Weighed On By Its Debt Load?

Apr 05
Is Exagen (NASDAQ:XGN) Weighed On By Its Debt Load?

Does Exagen (NASDAQ:XGN) Have A Healthy Balance Sheet?

Dec 03
Does Exagen (NASDAQ:XGN) Have A Healthy Balance Sheet?

Does Exagen (NASDAQ:XGN) Have A Healthy Balance Sheet?

Aug 06
Does Exagen (NASDAQ:XGN) Have A Healthy Balance Sheet?

Exagen Inc.'s (NASDAQ:XGN) Intrinsic Value Is Potentially 62% Above Its Share Price

Apr 07
Exagen Inc.'s (NASDAQ:XGN) Intrinsic Value Is Potentially 62% Above Its Share Price

Is Exagen (NASDAQ:XGN) Using Too Much Debt?

Mar 03
Is Exagen (NASDAQ:XGN) Using Too Much Debt?

Exagen issues preliminary testing revenue ahead of ICT chat

Jan 11

Would Shareholders Who Purchased Exagen's (NASDAQ:XGN) Stock Year Be Happy With The Share price Today?

Jan 05
Would Shareholders Who Purchased Exagen's (NASDAQ:XGN) Stock Year Be Happy With The Share price Today?

Exagen (XGN) Investor Presentation - Slideshow

Nov 20

Earnings and Revenue Growth Forecasts

NasdaqGM:XGN - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/202675-9-2-65
12/31/202565-12-8-106
12/31/202456-16-14-176
9/30/202456-17-6-5N/A
6/30/202457-17-6-6N/A
3/31/202456-19-14-14N/A
12/31/202353-24-15-14N/A
9/30/202352-32-30-29N/A
6/30/202353-35-34-32N/A
3/31/202346-45-37-33N/A
12/31/202246-47-36-32N/A
9/30/202245-40-37-32N/A
6/30/202243-39-36-31N/A
3/31/202248-31-28-25N/A
12/31/202148-27-23-20N/A
9/30/202148-23-19-18N/A
6/30/202147-20-16-15N/A
3/31/202143-17-16-15N/A
12/31/202042-17-15-14N/A
9/30/202040-17-15-14N/A
6/30/202039-29-14-14N/A
3/31/202041-31-11-11N/A
12/31/201940-30-10-10N/A
9/30/201940-31-8-8N/A
6/30/201938-18-9-8N/A
3/31/201935-18-8-8N/A
12/31/201832-18-9-9N/A
12/31/201727-33N/A-11N/A
12/31/201518-21N/A-12N/A
9/30/201518-21N/A-11N/A
6/30/201517-23N/A-10N/A
3/31/201515-17N/A-10N/A
12/31/201412-17N/A-11N/A
9/30/20149-23N/A-11N/A
6/30/20146-21N/A-10N/A
3/31/20144-19N/A-8N/A
12/31/20133-18N/A-7N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: XGN is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: XGN is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: XGN is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: XGN's revenue (13.7% per year) is forecast to grow faster than the US market (9.2% per year).

High Growth Revenue: XGN's revenue (13.7% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if XGN's Return on Equity is forecast to be high in 3 years time

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/30 11:39
End of Day Share Price 2024/12/30 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Exagen Inc. is covered by 8 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Mark MassaroBTIG
Kyle MiksonCanaccord Genuity
Charles DuncanCantor Fitzgerald & Co.